Clinical trial · Interventional

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study

NCT00004895CI-TRIAL-00007087completedPhase 2ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably. PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery.

Conditions

Conditions (10)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Colorectal Cancer	Malignant Colorectal Neoplasm	CURATED_BROADER	0.80
Constipation, Impaction, and Bowel Obstruction	—	UNRESOLVED	—
Extrahepatic Bile Duct Cancer	Malignant Extrahepatic Bile Duct Neoplasm	ALIAS	0.90
Gastric Cancer	Malignant Gastric Neoplasm	CURATED_BROADER	0.80
Gastrointestinal Stromal Tumor	Gastrointestinal Stromal Tumor	ONTOLOGY_EXACT	0.98
Nausea and Vomiting	—	UNRESOLVED	—
Ovarian Cancer	Malignant Ovarian Neoplasm	CURATED_EXACT	0.92
Pancreatic Cancer	Malignant Pancreatic Neoplasm	CURATED_EXACT	0.92
Peritoneal Cavity Cancer	Malignant Peritoneal Neoplasm	ALIAS

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
octreotide acetate	Drug	—	UNRESOLVED

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

DISEASE CHARACTERISTICS:

* Inoperable bowel obstruction secondary to cancer OR
* Metastatic or primary abdominal cancer
* Patient presents with vomiting
* Percutaneous gastrostomy tube allowed

PATIENT CHARACTERISTICS:

Age:

* Over 18

Performance status:

* ECOG 0-4

Life expectancy:

* Not specified

Hematopoietic:

* Not specified

Hepatic:

* Not specified

Renal:

* Not specified

Other:

* No documented hypersensitivity to octreotide
* Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* Not specified

Chemotherapy:

* Prior chemotherapy allowed

Endocrine therapy:

* Concurrent steroids allowed

Radiotherapy:

* Prior radiotherapy allowed

Surgery:

* Not specified

References

Publications (0)

Data not yet available

No reference posted for this study.

Registry

Dates and enrollment

Start: Oct 1, 1999
Primary completion: Oct 1, 2002
Completion: Oct 1, 2002
First posted: May 9, 2003
Last update posted: Jun 6, 2012
Lead sponsor: Northwestern University OTHER
Collaborators: National Cancer Institute (NCI)
Keywords: stage I colon cancer, stage II colon cancer, stage III colon cancer, stage IV colon cancer, stage I gastric cancer, stage II gastric cancer, stage III gastric cancer, stage IV gastric cancer, recurrent gastric cancer, stage I pancreatic cancer, stage II pancreatic cancer, stage III pancreatic cancer, stage IV pancreatic cancer, recurrent pancreatic cancer, stage I rectal cancer, stage II rectal cancer, stage III rectal cancer, stage IV rectal cancer, recurrent colon cancer, recurrent rectal cancer, stage I ovarian epithelial cancer, stage II ovarian epithelial cancer, stage III ovarian epithelial cancer, stage IV ovarian epithelial cancer, recurrent ovarian epithelial cancer, small intestine adenocarcinoma, small intestine lymphoma, small intestine leiomyosarcoma, localized extrahepatic bile duct cancer, unresectable extrahepatic bile duct cancer, recurrent extrahepatic bile duct cancer, recurrent small intestine cancer, constipation, impaction, and bowel obstruction, peritoneal cavity cancer, nausea and vomiting, gastrointestinal stromal tumor

Data updated 22 days agoSource updated Jun 6, 2012source: clinicaltrials

Locations

Brief summary (as posted)

Conditions (10)

Interventions (1)

Eligibility (as posted)

Publications (0)

Locations by country (1)